There are currently 845 clinical trials in Phoenix, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Phoenix Children's Hospital, GSK Investigational Site, Mayo Clinic Arizona and Mayo Clinic. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/15/2025
Locations: Phoenix Cardiovascular Research Group, Phoenix, Arizona
Conditions: Atrial Fibrillation
Register for Updates
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118
Recruiting
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona
Conditions: Myeloproliferative Neoplasms
Register for Updates
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +1 locations
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
NCT04375033
Recruiting
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona
Conditions: Opioid Use Disorder
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Recruiting
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/15/2025
Locations: Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Register for Updates
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Recruiting
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
08/15/2025
Locations: Abrazo Arizona Heart Hospital, Phoenix, Arizona
Conditions: Aortic Stenosis
Register for Updates
Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy
NCT06940271
Recruiting
This clinical trial studies whether a new multi-layer perinatal tissue allograft, MLG-Complete (Trademark), can be used to improve complications after nerve-sparing robot-assisted radical prostatectomy (RARP) in patients with prostate cancer that has not spread to other parts of the body (localized). Two major complications that can happen after complete surgical removal of the prostate (radical prostatectomy) include erectile dysfunction and urinary incontinence, both of which greatly affect a... Read More
Gender:
MALE
Ages:
45 years and above
Trial Updated:
08/15/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona
Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Arizona Oncology Associates, PC, Phoenix, Arizona
Conditions: Breast Cancer
Register for Updates
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222
Recruiting
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector per... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
08/15/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona
Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Register for Updates